{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-030141","form_type":"8-K","ticker":"NWBO","cik":"0001072379","company_name":"NORTHWEST BIOTHERAPEUTICS INC","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.778767+00:00","generated_at":"2026-06-18T08:12:11.723567+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Northwest Biotherapeutics secures $11M loan from Streeterville Capital","bullets":["Loan of $11,005,000 from Streeterville Capital, maturity 22 months, repayments start Nov 2023.","Interest at 8% per annum, with 10% original issue discount; prepayment allowed with 10% charge.","Proceeds for Sawston facility buildout, product approval preparation, and general operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-030141","json":"https://secwatch.observer/filing/0001104659-23-030141.json","markdown":"https://secwatch.observer/filing/0001104659-23-030141.md","text":"https://secwatch.observer/filing/0001104659-23-030141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923030141/0001104659-23-030141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923030141/tm238973_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:12:11.723567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a1b81b0a34d0a190b9952bb6013d0b8469ba1eb","claim":"NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.","evidence_excerpt":"On March 2, 2023, Northwest Biotherapeutics, Inc. (the \"Company\") entered into a Commercial Loan Agreement and Note (collectively, the \"Loan Agreement\") with Streeterville Capital, LLC (the \"Holder\") in the amount of $11,005,000.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923030141/0001104659-23-030141-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$11,005,000"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"22 months"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"b1192098257d9bafe8093fc3acf49ad92534a826","claim":"NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-03-02).","evidence_excerpt":"On March 2, 2023, Northwest Biotherapeutics, Inc. (the \"Company\") entered into a Commercial Loan Agreement and Note (collectively, the \"Loan Agreement\") with Streeterville Capital, LLC (the \"Holder\") in the amount of $11,005,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923030141/0001104659-23-030141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$11,005,000"},{"label":"Effective","value":"2023-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}